TICKERNERD
Menu
ALMSALMSHealthcare · Biotechnology

ALMS Stock Forecast: Alumis, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$25
+3.69% on the day

The 10 Wall Street analysts covering Alumis, Inc. hold a median 12-month price target of $39 — +54.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$3.2B
Ticker Nerd rank
51 / 100
Median analyst target
$39
Analysts covering
10
Total return, dividends reinvested
1W
−8.3%
1M
−7.2%
YTD
+159.3%
1Y
+476.5%
From 52W high
−16.5%
From 52W low
+540.8%
$4
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALMS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alumis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Accruals
81
Growth
69
Value
59
Volatility
50
Issuance
40
Size
30
Revisions
30
Quality
28

Momentum (94): The shares have been drifting up relative to others.

Quality (28): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALMS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALMS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26ALMSHigh $55Median $39Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $25Median $39High $55

The green dot is the last close — the median target sits +54.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Aug 2026HC Wainwright & Co.ReiteratesNeutral$25
3 Aug 2026HC Wainwright & Co.ReiteratesNeutral$25
19 May 2026Chardan CapitalMaintainsBuy—
19 May 2026Chardan CapitalMaintainsBuy$38 → $40
15 May 2026GuggenheimMaintainsBuy—
15 May 2026GuggenheimMaintainsBuy$32 → $34
15 May 2026HC Wainwright & Co.DowngradeNeutral—
15 May 2026HC Wainwright & Co.DowngradeNeutral$25
15 May 2026Wells FargoMaintainsOverweight$49 → $51
15 May 2026Wells FargoMaintainsOverweight—
30 Mar 2026Chardan CapitalMaintainsBuy—
30 Mar 2026HC Wainwright & Co.MaintainsBuy—
30 Mar 2026OppenheimerMaintainsOutperform—
20 Mar 2026Chardan CapitalMaintainsBuy—
20 Mar 2026Morgan StanleyMaintainsOverweight—
11 Mar 2026Raymond JamesInitiatesStrong Buy—
25 Feb 2026StifelInitiatesBuy—
21 Jan 2026Chardan CapitalInitiatesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
7 Jan 2026GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALMS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ALMS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Alumis, Inc. (ALMS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
442.8×

Cheaper than 2% of US stocks

Price / book
5.7×

Cheaper than 19% of US stocks

EV / EBITDA
−6.7×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
−37.7%

Higher than 7% of US stocks

Earnings growth (YoY)
−90.0%

Higher than 3% of US stocks

Gross margin
—
Operating margin
−6439.9%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−93.6%

Higher than 14% of US stocks

Return on assets
−45.3%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALMS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALMSAlumis, Inc.$3.2B
51
CLDXCelldex Therapeutics, Inc.$3.2B
31
ARQTArcutis Biotherapeutics, Inc.$3.2B
89
MBXMBX Biosciences, Inc.$3.3B
35
QUREUniQure NV$3.3B
54
IOVAIovance Biotherapeutics, Inc.$3.1B
90
NAMSNewAmsterdam Pharma Co. NV$3.1B
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alumis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALMS news & analysis

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

GlobeNewsWire · 13 Aug 2026positive

Alumis reported its second quarter 2026 financial results and highlighted recent achievements, including that 54% of patients in its ONWARD3 trial achieved complete skin clearance (PASI 100) at 48 weeks for envudeucitinib in psoriasis.

Why it matters — The strong PASI 100 efficacy data positions envudeucitinib as a potential new standard in psoriasis treatment, which could significantly impact Alumis's commercial prospects.

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Zacks Investment Research · 11 Aug 2026neutral

Zacks Investment Research highlighted Alumis, Inc. (ALMS) among four psoriasis drug stocks to watch during Psoriasis Awareness Month 2026, noting the company offers a diverse psoriasis opportunity.

Why it matters — The mention positions Alumis alongside other psoriasis-focused companies, drawing attention to ALMS as a psoriasis drug stock during a period of heightened investor awareness.

Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates

Benzinga · 11 Aug 2026positive

Alumis Inc. announced topline data from its ONWARD3 long-term extension study, showing that its investigational oral therapy envudeucitinib achieved leading skin clearance rates for patients with immune-mediated diseases.

Why it matters — The positive efficacy data for envudeucitinib strengthens Alumis's position in the psoriasis treatment landscape and supports the potential of its pipeline.

FAQ

Frequently asked questions about ALMS stock

What is the ALMS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Alumis, Inc. have a median 12-month price target of $39, with estimates ranging from $25 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALMS stock a buy right now?

Of the 10 analysts covering Alumis, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alumis, Inc. 51 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALMS?

As at 15 Aug 2026, Alumis, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will ALMS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +54.1% from the last close, and Ticker Nerd's factor model ranks Alumis, Inc. 51 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALMS stock forecast for 2030?

No analyst covering Alumis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALMS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $55 over the next 12 months.

How has ALMS stock performed over the past year?

Alumis, Inc. returned +476.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alumis, Inc. do?

Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for immune-mediated diseases, aiming to replace broad immunosuppression with precision medicines.

What is the latest news on ALMS?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements". Alumis reported its second quarter 2026 financial results and highlighted recent achievements, including that 54% of patients in its ONWARD3 trial achieved complete skin clearance (PASI 100) at 48 weeks for envudeucitinib in psoriasis.

Company

About Alumis, Inc.

Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for immune-mediated diseases, aiming to replace broad immunosuppression with precision medicines. The company leverages its proprietary precision data analytics platform, biological insights, and expertise in immunology to advance a late-stage portfolio of next-generation treatments. Key pipeline assets include ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor targeting plaque psoriasis and systemic lupus erythematosus; A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases; and programs addressing interferon regulatory factor 5 (IRF5) to correct immune dysfunction. Alumis Inc. focuses on optimizing patient outcomes across autoimmune disorders through innovative drug discovery, development, and potential commercialization efforts. Founded in 2021 and headquartered in South San Francisco, California, the company plays a significant role in the biotechnology sector by pioneering therapies that transform treatment paradigms for chronic immune conditions.

CEO Mr. Martin Babler Ph.D. · 237 employees · United States · https://www.alumis.com